Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (31-40 of 438) with videos related to

Pageof 44
Sort By:
Intervirology|September 8, 2016
The Role of IL28B Genotype in HCV-RNA Baseline LevelsLucio Boglione, Jessica Cusato, Giovanni Di Perri, et al.
Journal of Hepatology|May 28, 2013
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?Antonio D'Avolio, Jessica Cusato, Andrea Calcagno, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|July 15, 2019
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disordersLucio Boglione, Tommaso Lupia, Giuseppe Cariti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2013
Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid"Andrea Calcagno, Antonio D'Avolio, Giovanni Di Perri, et al.
Journal of Pharmaceutical and Biomedical Analysis|April 29, 2014
Therapeutic drug monitoring of intracellular anti-infective agentsAntonio D'Avolio, Debora Pensi, Lorena Baietto, et al.
Journal of Clinical Microbiology|October 6, 2006
Disseminated gonococcal infection in an immunocompetent patient caused by an imported Neisseria gonorrhoeae multidrug-resistant strainIvano Dal Conte, Stefania Starnino, Giovanni Di Perri, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsMarco Siccardi, Jonathan Schapiro, Giovanni Di Perri, et al.
Journal of Hepatology|March 26, 2014
Triple or dual therapy for HCV-1 naive patients? Optimizing selection toolsLucio Boglione, Amedeo De Nicolò, Giovanni Di Perri, et al.
Antiviral Therapy|September 11, 2019
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis CLucio Boglione, Amedeo De Nicolò, Giovanni Di Perri, et al.
European Journal of Public Health|March 25, 2017
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3Lucio Boglione, Jessica Cusato, Giuseppe Cariti, et al.
Pageof 44

Showing results (31-40 of 438) with videos related to

Sort By:
Pageof 44
Intervirology|September 8, 2016
The Role of IL28B Genotype in HCV-RNA Baseline LevelsLucio Boglione, Jessica Cusato, Giovanni Di Perri, et al.
Journal of Hepatology|May 28, 2013
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?Antonio D'Avolio, Jessica Cusato, Andrea Calcagno, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|July 15, 2019
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disordersLucio Boglione, Tommaso Lupia, Giuseppe Cariti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2013
Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid"Andrea Calcagno, Antonio D'Avolio, Giovanni Di Perri, et al.
Journal of Pharmaceutical and Biomedical Analysis|April 29, 2014
Therapeutic drug monitoring of intracellular anti-infective agentsAntonio D'Avolio, Debora Pensi, Lorena Baietto, et al.
Journal of Clinical Microbiology|October 6, 2006
Disseminated gonococcal infection in an immunocompetent patient caused by an imported Neisseria gonorrhoeae multidrug-resistant strainIvano Dal Conte, Stefania Starnino, Giovanni Di Perri, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsMarco Siccardi, Jonathan Schapiro, Giovanni Di Perri, et al.
Journal of Hepatology|March 26, 2014
Triple or dual therapy for HCV-1 naive patients? Optimizing selection toolsLucio Boglione, Amedeo De Nicolò, Giovanni Di Perri, et al.
Antiviral Therapy|September 11, 2019
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis CLucio Boglione, Amedeo De Nicolò, Giovanni Di Perri, et al.
European Journal of Public Health|March 25, 2017
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3Lucio Boglione, Jessica Cusato, Giuseppe Cariti, et al.
Pageof 44